Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalisation and death by nearly 90 per cent as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the US market.Currently all COVID-19 treatments used in the US require an IV or injection. Competitor Merck's COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.Pfizer said it will ask the FDA and international regulators to authorise its pill as soon as possible, after independent experts recommended halting the company's study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.
Load More
Load More